Federal Register of Legislation - Australian Government

Primary content

PB 57 of 2020 Determinations/Health as made
This instrument amends the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019) to make changes to the pharmaceutical benefits and ingredients in relation to which particular rules apply for ascertaining the Commonwealth price payable to an approved medical practitioner or an approved pharmacist for supply, and to make changes to the list of pharmaceutical benefits that must be supplied in complete packs.
Administered by: Health
Registered 30 Jun 2020

PB 57 of 2020

 

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 4)

 

National Health Act 1953

___________________________________________________________________________

 

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under paragraph 98C(1) of the National Health Act 1953.

 

 

Dated   29th June 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health


___________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 4).

(2)          This Instrument may also be cited as PB 57 of 2020.

2          Commencement

This Instrument commences on 1 July 2020.

3          Amendments to National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019

Schedule 1 amends the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019.

 

 

                     


Schedule 1     Amendments

[1]        Part 1, Section 6 (definition of extemporaneouslyprepared pharmaceutical benefit)

omit: Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2015 (PB 64 of 2015)

substitute: Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020 (PB 66 of 2020)

[2]        Part 2, Subsection 7(2)

omit: Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2015 (PB 64 of 2015)

substitute: Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020 (PB 66 of 2020)

[3]        Part 2, Section 7 (Note)

omit: Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2015 (PB 64 of 2015)

substitute: Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020 (PB 66 of 2020)

[4]        Schedule 4, after entry for Budesonide with formoterol in the form Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses, 2

insert:

Budesonide with formoterol

Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses

[5]        Schedule 4, omit entry for Mepolizumab

[6]        Schedule 4, after entry for Salmeterol

insert:

Semaglutide

Solution for injection 2 mg in 1.5 mL pre-filled pen

Semaglutide

Solution for injection 4 mg in 3 mL pre-filled pen